Search

Jogeshwar Mukherjee Phones & Addresses

  • 27 Exploration, Irvine, CA 92618
  • 27 Pembroke, Irvine, CA 92618
  • Beavercreek, OH
  • Chicago, IL
  • Orange, CA

Work

Company: Uc irvine Jun 2001 Position: Professor

Education

Degree: High school graduate or higher

Skills

Research • Teaching • Public Speaking • University Teaching • Science • Higher Education • Student Affairs • Molecular Biology • Lifesciences • Biochemistry • Spectroscopy • Life Sciences • Chemistry • Neuroscience • Clinical Research • Drug Discovery • Cancer • Medical Imaging • Clinical Trials • Biotechnology

Industries

Research

Resumes

Resumes

Jogeshwar Mukherjee Photo 1

Professor

View page
Location:
Irvine, CA
Industry:
Research
Work:
Uc Irvine
Professor

Kettering Health Network Sep 1997 - May 2001
Associate Professor

University of Chicago Nov 1986 - Aug 1997
Assistant Professor
Skills:
Research
Teaching
Public Speaking
University Teaching
Science
Higher Education
Student Affairs
Molecular Biology
Lifesciences
Biochemistry
Spectroscopy
Life Sciences
Chemistry
Neuroscience
Clinical Research
Drug Discovery
Cancer
Medical Imaging
Clinical Trials
Biotechnology

Publications

Us Patents

Β-Amyloid And Neurofibrillary Tangle Imaging Agents

View page
US Patent:
7737183, Jun 15, 2010
Filed:
Oct 17, 2007
Appl. No.:
11/873941
Inventors:
Jogeshwar Mukherjee - Irvine CA, US
Elizabeth Head - Irvine CA, US
Crystal Wang - La Palma CA, US
Pooja C. Patel - Stockton CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/13
C07C 255/00
US Classification:
514579, 558409
Abstract:
Compounds, compositions and methods are contemplated in which senile plaques and/or neurofibrillary tangles are labeled using compounds with improved permeability across the blood brain barrier and improved selective binding to senile plaques and/or neurofibrillary tangles. Contemplated compounds are derivatives of FDDNP or curcumin, which most preferably have improved solubility in aqueous solvents. Labeling is typically performed using a PET detectable label, and especially C and F.

Compositions And Methods Related To Serotonin 5-Ht1A Receptors

View page
US Patent:
RE43688, Sep 25, 2012
Filed:
Jul 21, 2011
Appl. No.:
13/187728
Inventors:
Jogeshwar Mukherjee - Irvine CA, US
Neil Saigal - Fresno CA, US
Harsh Saigal, legal representative - Fresno CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/55
C07D 401/00
A61K 49/04
A61K 31/497
C07D 241/04
US Classification:
424 94, 544360, 544358, 51425212, 51421301
Abstract:
Contemplated substituted arylpiperazinyl compounds, and most preferably F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with F-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.

Labeled Alpha4Beta2 Ligands And Methods Therefor

View page
US Patent:
8378109, Feb 19, 2013
Filed:
Dec 1, 2005
Appl. No.:
11/721145
Inventors:
Jogeshwar Mukherjee - Irvine CA, US
Ramaiah Pichika - Oregon CA, US
Steven Potkin - Irvine CA, US
Frances Leslie - Irvine CA, US
Sankha Chattopadhyay - Bidhannagar, IN
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07D 401/12
US Classification:
5462764, 5462791
Abstract:
Contemplated compositions and methods are employed to bind in vitro and in vivo to an α4β2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with α4ββ2 dysfunction.

Compositions And Methods Related To Serotonin 5-Ht1A Receptors

View page
US Patent:
20070196271, Aug 23, 2007
Filed:
Jan 24, 2007
Appl. No.:
11/626797
Inventors:
Jogeshwar Mukherjee - Irvine CA, US
Neil Saigal - Fresno CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 51/00
C07D 403/02
US Classification:
424001110, 514252140, 514253010, 514255030, 544295000, 544360000
Abstract:
Contemplated substituted arylpiperazinyl compounds, and most preferably F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with F-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.

Imaging Agents For Monitoring Changes Of Dopamine Receptors And Methods Of Using Thereof

View page
US Patent:
20080319310, Dec 25, 2008
Filed:
Apr 25, 2008
Appl. No.:
12/110135
Inventors:
Jogeshwar Mukherjee - Irvine CA, US
George Chandy - Laguna Beach CA, US
Norah Milne - Mission Viejo CA, US
Ping H. Wang - Irvine CA, US
Balu Easwaramoorthy - New York NY, US
Joseph Mantil - Dayton OH, US
International Classification:
A61B 5/055
US Classification:
600420
Abstract:
The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes and related to monitor disease progression or treatment efficacy of candidate drugs.
Jogeshwar M Mukherjee from Irvine, CA, age ~67 Get Report